Immune responses to NY--ESO--1 and MAGE--A3 peptides in hepatocellular carcinoma patients
Hongsong Chen(Inner Mongolia University for Nationalities), Weifeng Chen(Peking University), Cong Xu(Tongji Hospital), Ran Fei(Peking University), Qin Li-ling, Ming-hui Mei(Affiliated Hospital of Guilin Medical College), Huagang Zhang(Albert Einstein College of Medicine), Lai Wei(Tongji University)
Immunological Journal
January 1, 2006
Cited by 0
Related Papers
New progress in the pharmacology of protocatechuic acid: A compound ingested in daily foods and herbs frequently and heavily
|Pharmacological Research|2020|301
Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma
|Journal of Experimental & Clinical Cancer Research|2015|271
Functional Roles of Chemokine Receptor CCR2 and Its Ligands in Liver Disease
|Frontiers in Immunology|2022|122
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease
|Journal of Hepatology|2021|118